$HBAN

Street Calls of the Week

Investing.com’s Wall Street analyst recap covers Huntington Bancshares (BofA cuts to Neutral, PT $18.50), Clorox (Jefferies cuts to Hold, expects FY27 guidance ~6% below consensus), Ribbon Communications (B. Riley upgrades to Buy, PT $3.30), New Oriental Education (Macquarie keeps Neutral, PT up 15% citing $500M capital returns), and AXT (Needham upgrades to Buy, PT $90).

Original reporting
Published Aug 2, 2026, 10:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 2, 2026, 10:17 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$HBAN
Bearish
medium confidence
Mentioned
$HBAN · $CLX · $RBBN · $EDU · $AXTI
Relevance
4/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$HBANBearishMed
01

Why it matters

The actionable element is the direction and rationale of the analyst revisions, which can drive near-term relative performance and options positioning, but the piece itself is not a primary disclosure like an earnings print or regulatory filing.

02

Market read

Traders can use the rating and target changes as catalysts for short-term positioning, especially for RBBN and AXTl where the notes are explicitly bullish.

03

What to watch

The recap does not provide the magnitude of actual price moves or the full model assumptions behind EPS/multiple changes, so traders should verify whether the notes reflect new data versus re-interpretation.

Relevance 4/10Novelty 4/10Timing: analyst note recap for the week, published pre-market today

Background

This is a weekly recap of Wall Street analyst takeaways, summarizing rating changes and price-target revisions across five US-listed names.

Company-level read

Ticker impact

$HBANBearishMedium confidence
Context

BofA cuts Huntington Bancshares to Neutral and trims its price target to $18.50, citing NII value leakage and lowered EPS estimates.

Expected impact

Bias toward downside or underperformance versus prior Buy expectations.

Evidence & confidence

The article is a direct analyst downgrade with explicit EPS and price-target reductions tied to NII weakness.

$CLXBearishMedium confidence
Context

Jefferies downgrades Clorox to Hold, saying its bullish thesis was wrong as soft share trends persist and FY27 guidance is expected below consensus.

Expected impact

Bias toward continued multiple compression or limited upside until execution improves.

Evidence & confidence

The note explicitly expects FY27 guidance about 6% below consensus midpoint and flags higher reinvestment costs.

$RBBNBullishMedium confidence
Context

B. Riley upgrades Ribbon Communications to Buy, raising its price target to $3.30 and pointing to a guidance reset plus IP/Optical bookings and a 1.25 book-to-bill.

Expected impact

Bias toward upside as the market reprices from Neutral to Buy with a higher target.

Evidence & confidence

The upgrade is tied to concrete operational signals (book-to-bill 1.25) and a valuation multiple framework.

$EDUNeutralMedium confidence
Context

Macquarie upgrades New Oriental Education to Neutral and boosts its price target 15%, citing a $500 million capital return package offsetting operational drag.

Expected impact

Likely range-bound to mildly positive, with upside capped by overseas restructuring risk.

Evidence & confidence

The article balances improved Q4 revenue and margins with caution on FY27 margin growth and restructuring costs.

$AXTIBullishMedium confidence
Context

Needham upgrades AXT Inc. to Buy, sets a $90 price target, and cites earnings and forward guidance beats plus expanded indium phosphide substrate capacity.

Expected impact

Bias toward upside if investors buy into the capacity and contract-driven growth ramp.

Evidence & confidence

The upgrade includes specific catalysts: earnings blowout, capacity doubling plan, and fresh contracts tied to optical networking demand.

Market effects

Broad read-through to bank NII sensitivity, consumer staples margin durability, and optical networking execution risk; could shift relative positioning within each theme.

Limited direct regional spillover; mostly US-listed single-name valuation resets.

Minimal global macro linkage; mostly company-specific analyst revisions.

Counterpoint

Analyst upgrades/downgrades may lag fundamentals; for HBAN and CLX, the market may already be pricing NII and share/margin pressure, limiting incremental impact.

Key entities

  • Huntington Bancshares Incorporated

    BofA downgrades to Neutral and cuts price target to $18.50 citing NII weakness and lowered EPS estimates.

  • Clorox Co

    Jefferies downgrades to Hold, expecting FY27 guidance about 6% below consensus midpoint due to persistent share softness.

  • Ribbon Communications Inc

    B. Riley upgrades to Buy with a $3.30 target, citing a guidance reset and strong IP/Optical bookings (book-to-bill 1.25).

  • New Oriental Education & Technology

    Macquarie upgrades to Neutral and raises target 15% on a $500 million capital return package offsetting operational drag.

  • AXT Inc.

    Needham upgrades to Buy with a $90 target, citing earnings and forward guidance beats plus expanded indium phosphide substrate capacity.

Related articles

$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

$CLXMedAI 8/10

Clorox fiscal 2027 outlook: inflation and value shoppers weigh

Clorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.

$CLXMedAI 8/10

Clorox forecasts upbeat annual sales as demand improves

Reuters reports Clorox (Pine-Sol maker) forecast fiscal 2027 net sales growth of 13% to 14%, above analysts’ 12.8% estimate, and adjusted EPS of $5.70 to $6 versus $5.97 expected. Q4 sales fell 2% to $1.95B but beat $1.90B. Gross margin dropped to 41.3%. Clorox cited improving demand amid a challenging cost and value-seeking environment.

$CLXMedAI 8/10

CLOROX CO /DE/ (CLX): Results of Operations and Financial Condition

CLOROX CO /DE/ (CLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-pressreleasedatedaug.htm EX-99.1 Document Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook Delivers Q4 results in line with expectations while advancing strategic investments OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reporte

$AXTIMedAI 8/10

AXT (AXTI) Q2 2026 Earnings Call Transcript

AXT (AXTI) held its Q2 2026 earnings call, reporting revenue of $47.6M, up 77% vs Q1 2026 and 164% vs Q2 2025. Indium phosphide revenue was $30.7M. Non-GAAP gross margin was 45.0%. Non-GAAP net profit was $11.9M ($0.19/share). Cash rose to $749M after a $632M secondary offering. The company also discussed supply prepayments and a plan to list its Tongmei subsidiary via Hong Kong instead of China’s STAR Market.